The estimated Net Worth of Otello Stampacchia is at least $218 Million dollars as of 14 October 2020. Otello Stampacchia owns over 450,000 units of Morphic Inc stock worth over $217,603,948 and over the last 5 years he sold MORF stock worth over $0. In addition, he makes $260,016 as Independent Director at Morphic Inc.
Sign up
Otello Stampacchia MORF stock SEC Form 4 insiders trading
Otello has made over 2 trades of the Morphic Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 450,000 units of MORF stock worth $8,550,000 on 14 October 2020.
The largest trade he's ever made was buying 450,000 units of Morphic Inc stock on 14 October 2020 worth over $8,550,000. On average, Otello trades about 97,222 units every 79 days since 2019. As of 14 October 2020 he still owns at least 3,818,283 units of Morphic Inc stock.
You can see the complete history of Otello Stampacchia stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Otello Stampacchia biography
Dr. Otello Stampacchia Ph.D. serves as Independent Director of the Company. He has served as founder and Managing Director of Omega Funds since 2004. Previously, Dr. Stampacchia was in charge of life sciences direct investments at AlpInvest Partners B.V. from 2001 to 2003, and from 2000 to 2001, Dr. Stampacchia was the portfolio manager of the Lombard Odier Immunology Fund. Previously, Dr. Stampacchia was a member of the healthcare corporate finance and mergers and acquisitions team at Goldman Sachs Group, Inc. from 1997 to 2000, Before joining Goldman Sachs, Dr. Stampacchia helped co-found the healthcare investment activities at Index Securities, now Index Ventures, Inc. Dr. Stampacchia is currently a member of the boards of directors of Replimune Group, Inc. and Kronos Bio, Inc. Dr. Stampacchia also serves on the board of directors of a private company and previously served on the boards of Gossamer Bio, Inc. and ESSA Pharma, Inc. He has a Ph.D. degree in Molecular Biology from the University of Geneva and a European Ph.D. in Biotechnology (EDBT) from the European Association for Higher Education in Biotechnology. He has an M.S. in Genetics from Universa' degli Studi di Pavia. Stampacchia is qualified to serve on our board of directors because of his experience investing in life sciences companies and working with and serving on the boards of directors of various life sciences companies.
What is the salary of Otello Stampacchia?
As the Independent Director of Morphic Inc, the total compensation of Otello Stampacchia at Morphic Inc is $260,016. There are 10 executives at Morphic Inc getting paid more, with Timothy Springer having the highest compensation of $1,260,500.
How old is Otello Stampacchia?
Otello Stampacchia is 51, he's been the Independent Director of Morphic Inc since 2018. There are 9 older and 8 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
What's Otello Stampacchia's mailing address?
Otello's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Insiders trading at Morphic Inc
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, and Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
What does Morphic Inc do?
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
What does Morphic Inc's logo look like?
Complete history of Otello Stampacchia stock trades at Morphic Inc, Gossamer Bio, and Kronos Bio
Morphic Inc executives and stock owners
Morphic Inc executives and other stock owners filed with the SEC include:
-
Timothy Springer,
Founder, Independent Director -
Alexey Lugovskoy,
Chief Development Officer -
Dr. Praveen P. Tipirneni M.D.,
CEO, Pres & Director -
William DeVaul,
General Counsel, Secretary -
Praveen Tipirneni,
President, Chief Executive Officer, Director -
Dr. Marc Schegerin M.B.A., M.D.,
CFO & COO -
Bruce Rogers,
Chief Scientific Officer -
Vikas Goyal,
Independent Director -
Gustav Christensen,
Independent Chairman of the Board -
Joseph Slattery,
Independent Director -
Otello Stampacchia,
Independent Director -
Norbert Bischofberger,
Independent Director -
Amir Nashat,
Independent Director -
Dr. Timothy A. Springer Ph.D.,
Founder, Independent Director & Member of Scientific Advisory Board -
Nilesh Kumar,
Independent Director -
Peter Linde,
Chief Medical Officer -
Robert Farrell,
Senior Vice President - Finance, Chief Accounting Officer -
Marc Schegerin,
Chief Financial Officer, Chief Operating Officer -
Adrian S. Ray Ph.D.,
Sr. VP and Head of Biology & Translation -
Blaise Lippa,
Sr. VP of Molecular Discovery -
William D. DeVaul Esq.,
Gen. Counsel & Sec. -
Dr. Bruce N. Rogers,
Chief Scientific Officer -
Robert E. Farrell Jr., CPA, CPA,
Sr. VP of Fin./Operations & Chief Accounting Officer -
Susannah Gray,
-
Nisha Nanda,
-
Martin Edwards,
-
Holdings A/S Novo,
10% owner -
Plc Gsk,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Simon Peter Cooper,
CMO